A5053985956- Nonmelanoma Skin Cancer Studies
- Cutaneous Melanoma Detection and Management
- Oral Health Pathology and Treatment
- Cutaneous lymphoproliferative disorders research
- Nail Diseases and Treatments
- Autoimmune Bullous Skin Diseases
- Skin Diseases and Diabetes
- Lymphoma Diagnosis and Treatment
- Inflammatory Myopathies and Dermatomyositis
- Chronic Lymphocytic Leukemia Research
- Dermatological and Skeletal Disorders
- Pharmaceutical studies and practices
- Obsessive-Compulsive Spectrum Disorders
- Opioid Use Disorder Treatment
- Cancer Immunotherapy and Biomarkers
- Melanoma and MAPK Pathways
- Health Systems, Economic Evaluations, Quality of Life
- Cancer and Skin Lesions
- Cancer Genomics and Diagnostics
- Case Reports on Hematomas
- Chemotherapy-related skin toxicity
- Autism Spectrum Disorder Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Dermatological and COVID-19 studies
Mayo Clinic in Arizona
2021-2025
WinnMed
2021
Duke University
2020
Abstract Cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in humans and kills as many people annually melanoma. The mutational transcriptional landscape cSCC has identified driver mutations associated with disease progression well key pathway activation pre-cancerous lesions. understanding changes respect to high-risk clinical/histopathological features outcome poor. Here, we examine stage-matched, outcome-differentiated clinicopathologic risk factors using whole...
Abstract Background Combination immune checkpoint blockade targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte associated 4 (CTLA-4) leads to high response rates improved survival in patients with advanced cutaneous melanoma (CM). Less is known about the efficacy of this combination acral lentiginous (ALM). Objectives To determine PD-1 CTLA-4 a diverse, real-world population ALM. Methods This multi-institutional retrospective study analysed histologically confirmed...
Cutaneous lichen planus (LP) is a recalcitrant, difficult-to-treat, inflammatory skin disease characterized by pruritic, flat-topped, violaceous papules on the skin. Baricitinib an oral Janus kinase (JAK) 1/2 inhibitor that interrupts signaling pathway of interferon gamma (IFN)-γ, cytokine implicated in pathogenesis LP.
Background and objectives With multiple medications indicated for mineral metabolism, dialysis providers can apply various strategies to achieve target phosphate parathyroid hormone (PTH) levels. We describe common prescribing patterns practice variation in metabolism treatment over the last decade. Design, setting, participants, & measurements In a cohort of adults initiating hemodialysis at Dialysis Clinic, Inc. facilities, we assessed prescriptions vitamin D sterols, binders,...
This report evaluates the use of timolol in 2 patients with long-term hydroxyurea and lower-extremity ulcers resistant to other treatments.
Background: Cutaneous lichen planus (LP) is a recalcitrant, difficult-to-treat, inflammatory skin disease characterized by pruritic, flat-topped, violaceous papules on the skin. Baricitinib an oral Janus kinase (JAK) 1/2 inhibitor that interrupts signaling pathway of interferon (IFN)-γ, cytokine implicated in pathogenesis LP. Methods: In this phase II trial, twelve patients with cutaneous LP received baricitinib 2 mg daily for 16 weeks, accompanied in-depth spatial, single-cell, and bulk...
Drug repurposing is an attractive strategy for therapy development, particularly in rare diseases where traditional drug development approaches may be challenging owing to high cost and small numbers of patients. In this study, we used a identification pipeline identify candidate targetable drivers disease corresponding therapies through application causal reasoning using combination open-access resources transcriptomics data. We optimized our approach on psoriasis as model, demonstrating...